First ever robotic coronary angioplasties completed in Germany by Robocath

A firm which designs, manufactures, and markets cardiovascular robotic systems to treat vascular ailments, Robocath publicized today how it had successfully finished its first-ever robotic coronary angioplasties in Germany, with R-One™. Professor Michael Haude is an esteemed and highly trained interventional cardiologist based at Rheinland Klinikum Neuss Lukaskrankenhaus. Michael Haude, along with his team, performed the Percutaneous Coronary Interventions.

The Director of Medical Clinic at Rheinland Klinikum Neuss Lukaskrankenhaus, Professor Michael Haude expressed his pride over being the very first user of this newest European robotic solution, in Germany, for Percutaneous Coronary Interventions. He added how these robotic interventions lead the road to a new era in interventional cardiology. Professor Haude stated how R-One™ is greatly advantageous for practitioners and will considerably advance their working conditions which, resultantly, will be advantageous to patient care. He concluded by saying how he and his team were excited to incorporate this robotic-assisted platform for Percutaneous Coronary Interventions into their everyday clinical operations.

Robocath’s chairman and founder, Philippe Bencteux stated how they were very pleased with how much these procedures had accomplished he expressed his gratitude to Professor Haude’s team for their fervor. He stated how Professor Haude had more than 30 years of experience when it comes to interventional cardiology, and that they depend on capitalizing on this type of experience to advance clinical evidence and showcase the complete advantages of their solution.

The chief executive officer of Robocath, Lucien Goffart stated how these initial procedures based in Germany are per their expansion strategy. He expressed his pride at accomplishing this significant strategic step and in witnessing their first robot used in this crucial market.

Robocath was founded by Philippe Bencteux, MD, in 2009. The firm designs, generates, and markets robotic solutions for the treatment of cardiovascular ailments.